Beijing Hanmi Pharmaceutical Co., Ltd.

MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations.

Hanmi Pharmaceutical has launched Gugutams in Mexico under the brand name Aditams, marking the company's third product entry into Latin America following a 2020 export agreement with Laboratorios Silanes.

Phase I/II trial demonstrates 60% objective response rate for Tivumecirnon plus Keytruda in EBV-positive gastric cancer patients, including complete and partial responses.

Hanmi Pharmaceutical presented clinical trial progress for BH3120, a novel dual-targeting immunotherapy, at the SITC conference.

Hanmi Pharmaceutical's BH3120, a novel dual-targeting immunotherapy, is progressing through Phase 1 trials, demonstrating a favorable safety profile in advanced solid tumor patients.

Hanmi Pharmaceutical's BH3120, a novel dual-targeting antibody, is progressing through Phase 1 trials, showing no dose-limiting toxicities in advanced solid tumor patients.

Hanmi Pharmaceutical has expedited the launch of its anti-obesity drug candidate, efpeglenatide, to the second half of 2026.

Hanmi Pharmaceutical is accelerating the launch of Efeglenatide, an obesity drug, to the second half of 2026, ahead of its initially planned 2027 release.

Bridge Biotherapeutics' BBT-877, a first-in-class autotaxin inhibitor, is undergoing Phase 2 trials with data expected in April, showing promising safety and efficacy.

Hanmi Pharmaceutical is progressing HCP1803, a novel low-dose triple antihypertensive drug, through Phase 3 clinical trials in Korea, expected to conclude in the second half of next year.